532 related articles for article (PubMed ID: 24726860)
1. Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs.
Truxova I; Pokorna K; Kloudova K; Partlova S; Spisek R; Fucikova J
Immunol Lett; 2014 Jul; 160(1):39-49. PubMed ID: 24726860
[TBL] [Abstract][Full Text] [Related]
2. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials.
Fučíková J; Rožková D; Ulčová H; Budinský V; Sochorová K; Pokorná K; Bartůňková J; Špíšek R
J Transl Med; 2011 Dec; 9():223. PubMed ID: 22208910
[TBL] [Abstract][Full Text] [Related]
3. A comparative analysis of serum and serum-free media for generation of clinical grade DCs.
Napoletano C; Pinto D; Bellati F; Taurino F; Rahimi H; Tomao F; Panici PB; Rughetti A; Frati L; Nuti M
J Immunother; 2007; 30(5):567-76. PubMed ID: 17589298
[TBL] [Abstract][Full Text] [Related]
4. A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines.
Jarnjak-Jankovic S; Hammerstad H; Saebøe-Larssen S; Kvalheim G; Gaudernack G
BMC Cancer; 2007 Jul; 7():119. PubMed ID: 17608923
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation.
Toniolo PA; Liu S; Yeh JE; Moraes-Vieira PM; Walker SR; Vafaizadeh V; Barbuto JA; Frank DA
J Immunol; 2015 Apr; 194(7):3180-90. PubMed ID: 25725100
[TBL] [Abstract][Full Text] [Related]
6. Combined TLR stimulation with Pam3Cys and Poly I: C enhances Flt3-ligand dendritic cell activation for tumor immunotherapy.
Lim SN; Kuhn S; Hyde E; Ronchese F
J Immunother; 2012; 35(9):670-9. PubMed ID: 23090076
[TBL] [Abstract][Full Text] [Related]
7. Using dendritic cells to evaluate how Burkholderia cenocepacia clonal isolates from a chronically infected cystic fibrosis patient subvert immune functions.
Guadalupe Cabral M; Pereira M; Silva Z; Iria I; Coutinho C; Lopes A; Sá-Correia I; Videira PA
Med Microbiol Immunol; 2017 Apr; 206(2):111-123. PubMed ID: 27987042
[TBL] [Abstract][Full Text] [Related]
8. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells.
Verdijk RM; Mutis T; Esendam B; Kamp J; Melief CJ; Brand A; Goulmy E
J Immunol; 1999 Jul; 163(1):57-61. PubMed ID: 10384099
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cell maturation with poly(I:C)-based versus PGE2-based cytokine combinations results in differential functional characteristics relevant to clinical application.
Möller I; Michel K; Frech N; Burger M; Pfeifer D; Frommolt P; Veelken H; Thomas-Kaskel AK
J Immunother; 2008 Jun; 31(5):506-19. PubMed ID: 18463533
[TBL] [Abstract][Full Text] [Related]
10. Fast generation of dendritic cells.
Kvistborg P; Boegh M; Pedersen AW; Claesson MH; Zocca MB
Cell Immunol; 2009; 260(1):56-62. PubMed ID: 19818956
[TBL] [Abstract][Full Text] [Related]
11. Standardized generation of fully mature p70 IL-12 secreting monocyte-derived dendritic cells for clinical use.
Spisek R; Bretaudeau L; Barbieux I; Meflah K; Gregoire M
Cancer Immunol Immunother; 2001 Oct; 50(8):417-27. PubMed ID: 11726136
[TBL] [Abstract][Full Text] [Related]
12. Comparison of media and serum supplementation for generation of monophosphoryl lipid A/interferon-γ-matured type I dendritic cells for immunotherapy.
Kolanowski ST; Sritharan L; Lissenberg-Thunnissen SN; Van Schijndel GM; Van Ham SM; ten Brinke A
Cytotherapy; 2014 Jun; 16(6):826-34. PubMed ID: 24529557
[TBL] [Abstract][Full Text] [Related]
13. Two-step maturation of immature DCs with proinflammatory cytokine cocktail and poly(I:C) enhances migratory and T cell stimulatory capacity.
Kim HJ; Kim HO; Lee K; Baek EJ; Kim HS
Vaccine; 2010 Apr; 28(16):2877-86. PubMed ID: 20156531
[TBL] [Abstract][Full Text] [Related]
14. Generation of Aspergillus- and CMV- specific T-cell responses using autologous fast DC.
Ramadan G; Konings S; Kurup VP; Keever-Taylor CA
Cytotherapy; 2004; 6(3):223-34. PubMed ID: 15203979
[TBL] [Abstract][Full Text] [Related]
15. A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine.
Park HJ; Jang GY; Kim YS; Park JH; Lee SE; Vo MC; Lee JJ; Han HD; Jung ID; Kang TH; Park YM
J Immunother Cancer; 2019 Feb; 7(1):60. PubMed ID: 30819254
[TBL] [Abstract][Full Text] [Related]
16. A functional comparison of mature human dendritic cells prepared in fluorinated ethylene-propylene bags or polystyrene flasks.
Kurlander RJ; Tawab A; Fan Y; Carter CS; Read EJ
Transfusion; 2006 Sep; 46(9):1494-504. PubMed ID: 16965575
[TBL] [Abstract][Full Text] [Related]
17. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
18. In-Depth Analysis of the Impact of Different Serum-Free Media on the Production of Clinical Grade Dendritic Cells for Cancer Immunotherapy.
Calmeiro J; Mendes L; Duarte IF; Leitão C; Tavares AR; Ferreira DA; Gomes C; Serra J; Falcão A; Cruz MT; Carrascal MA; Neves BM
Front Immunol; 2020; 11():593363. PubMed ID: 33613517
[TBL] [Abstract][Full Text] [Related]
19. Mature dendritic cells generated from patient-derived peripheral blood monocytes in one-step culture using streptococcal preparation OK-432 exert an enhanced antigen-presenting capacity.
Naito K; Ueda Y; Itoh T; Fuji N; Shimizu K; Yano Y; Yamamoto Y; Imura K; Kohara J; Iwamoto A; Shiozaki A; Tamai H; Shimizu T; Mazda O; Yamagishi H
Int J Oncol; 2006 Jun; 28(6):1481-9. PubMed ID: 16685449
[TBL] [Abstract][Full Text] [Related]
20. Addition of CpG ODN and Poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity.
Zhu M; Xu W; Su H; Huang Q; Wang B
Hum Vaccin Immunother; 2015; 11(7):1596-605. PubMed ID: 26039883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
